Biochemical Recurrence and Survival Prediction Models for the Management of Clinically Localized Prostate Cancer

Clinical Prostate Cancer

Volumn 2, Issue 4, 2004, Pages 220-227

  Tewari, Ashutosh ^a   Gamito, Eduard J ^b   Crawford, E David ^b   Menon, Mani ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Artificial neural networks; Genetic algorithms; Predictive modeling; Prognosis; Propensity scoring; Survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTIFICIAL NEURAL NETWORK; CANCER RECURRENCE; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DISEASE MODEL; GENETIC ALGORITHM; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROSTATE CARCINOMA; PROSTATECTOMY; RACE DIFFERENCE; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TREATMENT FAILURE;

EID: 16544393111     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.003     Document Type: Review

References (33)

1. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-1451.
2. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001; 165:1562-1568.
3. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomo-gram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90:766-771.
4. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17:1499-1507.
5. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 18:3352-3359.
6. Porter CR, O'Donnell C, Crawford ED, et al. Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study. Urology 2002; 60:831-835.
7. Porter CR, O'Donnell C, Crawford ED, et al. Artificial neural network model to predict biochemical failure following radical prostatectomy. Mol Urol 2001; 5:159-162.
8. Gamito EJ, Dayhoff J, Crawford ED, et al. Artificial neural network model to predict extent of tumor in men with clinically localized prostate cancer. Presented at: INNS-IEEE International Joint Conference on Neural Networks; July 15-19, 2001; Washington, DC.
9. Batuello JT, Gamito EJ, Crawford ED, et al. Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology 2001; 57:481-485.
10. Crawford ED, Batuello JT, Snow P, et al. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma. Cancer 2000; 88:2105-2109.
11. Tewari A, Issa M, El-Galley R, et al. Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multiinstitutional study. Mol Urol 2001; 5:163-169.
12. Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, and comorbidity. J Urol 2004; 171:1513-1519.
13. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998; 160:2428-2434.
14. Connolly JA, Shinohara K, Presti JC, Jr., et al. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996; 47:225-231.
15. Partin AW, Pearson JD, Landis PK, et al. Evaulation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43:649-659.
16. Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy to distinguish. Patterns of recurrence and cancer control. Urol Clin NorthAm 1997; 24:395-406.
17. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597.
18. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152:1821-1825.
19. Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158:1441-1445.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
21. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-2281.
22. Gum PA, Thamilarasan M, Watanabe J, et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 2001; 286:1187-1194.
23. Ioannidis JP, Galanos O, Katritsis D, et al. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. J Am Coll Cardiol 2001; 37:521-528.
24. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999; 150:327-333.
25. Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000; 163:143-145.
26. Bauer JJ, Connelly RR, Sesterhenn IA, et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 1997; 79:952-962.
27. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001; 58:393-399.
28. Potter SR, Miller MC, Mangold LA, et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999; 54:791-795.
29. Han M, Snow PB, Epstein JI, et al. A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 2000; 56:994-999.
30. Kattan MW. Nomograms. Introduction. Semin Urol Oncol 2002; 20:79-81.
31. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280:975-980.
32. Sweat SD, Bergstralh EJ, Slezak J, et al. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002; 168:525-529.
33. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91:2302-2314.